The Cephalosporin Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Cephalosporin Market:
https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report
According to The Business Research Company’s Cephalosporin Global Market Report 2024, The cephalosporin market size has grown steadily in recent years. It will grow from $17.04 billion in 2023 to $17.69 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to growing prevalence of bacterial infections, increasing antibiotic resistance, expanding surgical procedures and hospitalizations, rising awareness among healthcare professionals, regulatory support for antibiotic development..
The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $20.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to escalating global burden of infectious diseases, emerging bacterial resistance, continued growth in surgical interventions and healthcare-associated infections, increasing demand for broad-spectrum antibiotics, evolving reimbursement policies influencing market dynamics.. Major trends in the forecast period include technological advancements, regulatory landscape, market expansion with advance solution, collaborations and partnerships..
The growing prevalence of infectious diseases is expected to propel the growth of the cephalosporin market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can be transmitted from one individual to another through various means that cause diseases such as tuberculosis, malaria, and flu. Infectious diseases drive the demand for cephalosporin antibiotics, which are commonly used to treat infectious diseases caused by bacterial pathogens and can be prescribed for various types of infections due to their crucial role in managing and combating bacterial infections. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the growing prevalence of infectious diseases will drive the growth of the cephalosporin market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13402&type=smp
The cephalosporin market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Route Of Administration: Injection, Oral
3) By Application: Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Other Applications
Major companies operating in the cephalosporin market are focused on developing new products and therapies, such as advanced-generation cephalosporins, to combat antibiotic resistance and enhance their portfolio's effectiveness in treating a wider spectrum of bacterial infections. Ceftobiprole is a broad-spectrum cephalosporin antibiotic used to treat various bacterial infections, including skin and soft tissue infections and pneumonia. For instance, in July 2022, Mast Group Ltd., a UK-based manufacturer and supplier of clinical and industrial diagnostic products, launched Ceftobiprole 5µg in the MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera or Mabelio) is a broad-spectrum 5th-generation cephalosporin that is approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in several European countries. Ceftobiprole is a good alternative for targeted empirical therapy due to its broad range of activity, strong effectiveness against methicillin-resistant Staphylococcus aureus (MRSA), and favorable safety profile.
The cephalosporin market report table of contents includes:
1. Executive Summary
2.Cephalosporin Market Characteristics
3. Cephalosporin Market Trends And Strategies
4.Cephalosporin Market analysis
5. Cephalosporin Market Size And Growth
6.Cephalosporin Segmentation
7.Cephalosporin Regional And Country Analysis
.
.
.
27. Cephalosporin Competitive Landscape And Company Profiles
28.Cephalosporin Key Mergers And Acquisitions
29.Cephalosporin Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- Roche Holding AG
- Merck & Co. Inc.
- Novartis AG
- AbbVie Inc.
- AstraZeneca PLC
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Radiant Insights, Inc. data shows that China is the biggest contributor to the Cephalosporin revenue market, accounted for 41.13% of the total global market with a revenue of 1516.91 million USD in 2017, followed by India, 23.29% with a revenue of 858.72 million USD.
Download Free Sample Report @ https://www.radiantinsights.com/research/global-cephalosporin-market-2020-2026/request-sample NCPC is the largest company in the global Cephalosporin market, accounted for 7.55% of the revenue market share in 2017, followed by Union Chempharma and Qilu Antibiotics, accounted for 7.29% and 6.81% of the revenue market share in 2017.
The Cephalosporin industry is not concentrated, these manufacturers range from large multinational corporations to small privately owned companies compete in this industry.
The top five manufacturers account for only 29.88% of the revenue market.This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering• Union Chempharma• NCPC• Qilu Antibiotics• Lupin Pharmaceuticals• Hospira• Dhanuka Laboratories• Fukang• Dongying Pharmaceutical• Alkem• SALUBRIS• LIVZON• Hetero Drugs• CSPC• TEVA• Orchid Pharma• Taj Pharmaceuticals• Covalent Laboratories• United Laboratories• Aurobindo• Wockhardt• LKPC• HPGC• Huafangpharm On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into• First Generation• Second Generation• Third Generation• Fourth Generation By Application, this report focuses on Sales, Market share and Growth Rate of each application, can be divided into• Oral• Injection By Regions, this report splits global market into several key regions, with Sales, Revenue, Price and Gross Margin market share of top players in these regions, from 2014 to 2026 (forecast), like• China• USA• Europe• Japan• Korea• India• Southeast Asia• South America Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/global-cephalosporin-market-2020-2026 Table of Contents Global Cephalosporin Market Professional Survey Report 20191 Report Overview1.1 Definition and Specification1.2 Manufacturers and Region Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.3 Type Overview1.3.1 First Generation1.3.2 Second Generation1.3.3 Third Generation1.3.4 Fourth Generation1.4 Application Overview1.4.1 Oral1.4.2 Injection1.5 Industrial Chain1.5.1 Cephalosporin Industrial Chain1.5.2 Upstream1.5.3 Downstream 2.1 The Overall Market Performance(Volume)2.1.1 First Generation2.1.2 Second Generation2.1.3 Third Generation2.1.4 Fourth Generation2.2 The Overall Market Performance(Value)2.2.1 First Generation2.2.2 Second Generation2.2.3 Third Generation2.2.4 Fourth Generation 3 Global Cephalosporin Market Assessment by Application3.1 Overall Market Performance (Volume)3.2 Oral3.3 Injection Continued… Read all Reports of this category @ https://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare About Radiant InsightsRadiant Insights is a platform for companies looking to meet their market research and business intelligence requirements.
It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process.
The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
The Global Cephalosporin Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved.
The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.The report classifies the market into different segments.
These segments are studied in detail incorporating the market estimates and forecasts at regional and country level.
The segment analysis is useful in understanding the growth areas and probable opportunities of the market.Final Report will cover the impact of COVID-19 on this industry.Browse the complete Global Cephalosporin Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027 @ https://www.decisiondatabases.com/ip/1706-cephalosporin-market-reportThe report also covers the complete competitive landscape of the global Cephalosporin market with company profiles of key players such as: Union ChempharmaNCPCQilu AntibioticsLupin PharmaceuticalsHospiraDhanuka LaboratoriesFukangDongying PharmaceuticalAlkemSALUBRISLIVZONHetero DrugsCSPCTEVAOrchid PharmaTaj PharmaceuticalsCovalent LaboratoriesUnited LaboratoriesAurobindoWockhardtLKPCHPGCHuafangpharmThe detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.SEGMENTATIONS IN THE REPORT:By TypeFirst GenerationSecond GenerationThird GenerationFourth GenerationBy ApplicationOralInjectionBy Geography:North America (NA) – US, Canada, and MexicoEurope (EU) – UK, Germany, France, Italy, Russia, Spain & Rest of EuropeAsia-Pacific (APAC) – China, India, Japan, South Korea, Australia & Rest of APACLatin America (LA) – Brazil, Argentina, Peru, Chile & Rest of Latin AmericaMiddle East and Africa (MEA) – Saudi Arabia, UAE, Israel, South AfricaDownload Free Sample Report of Global Cephalosporin Market @ https://www.decisiondatabases.com/contact/download-sample-1706The Global Cephalosporin Market has been exhibited in detail in the following chapters –Chapter 1 Cephalosporin Market PrefaceChapter 2 Executive SummaryChapter 3 Cephalosporin Industry AnalysisChapter 4 Cephalosporin Market Value Chain AnalysisChapter 5 Cephalosporin Market Analysis By TypeChapter 6 Cephalosporin Market Analysis By ApplicationChapter 7 Cephalosporin Market Analysis By GeographyChapter 8 Competitive Landscape Of Cephalosporin CompaniesChapter 9 Company Profiles Of Cephalosporin IndustryPurchase the complete Global Cephalosporin Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-1706Other Reports by DecisionDatabases.com:Global Cypermethrin Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027Global Epichlorohydrin (ECH) Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
Acute bacterial skin and skin structure infections (ABSSSI) are the type of skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues.
Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI.
The ABSSSI market is expected to witness moderate growth owing to the increasing number of patients suffering from skin infections and large number of pipeline products, which are expected to receive approval during the forecast period.Get PDF Brochure Of This Research Report @https://www.coherentmarketinsights.com/insight/request-pdf/4273North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Impact of Coronavirus (COVID-19) PandemicAcute bacterial skin and skin structure infections (ABSSSI) antibiotics treatment is required for majority of patients with severe bacterial skin infection and the treatment might be delayed due to the pandemic.
Moreover, according to a study published in the Antimicrobial Agents and Chemotherapy journal, the monthly use of antibiotic therapy from March through June 2020 decreased by 151.5% per month compared with January 2018 through February 2020 - a 6.5% monthly reduction in use of antibiotics.The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 1,283.8 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027).Increasing research and development activities are expected to boost growth of the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.The major driver for the growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market is research and development of products and novel treatments by pharmaceutical and biopharmaceutical companies.
For instance, in August 2019, Basilea Pharmaceutica Ltd. announced positive topline results for the phase 3 TARGET study, evaluating ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).
According to the Centers for Disease Control and Prevention, the World Health Organization, and U.S. and European governments, patent expiration leads to the production of low priced and low cost generic drugs are easily accessible which leads to their overuse and misuse.
The Cephalosporin Drugs Market research report presents a comprehensive assessment of the market and contains thoughtful insights, historical data, facts, and industry-validated market data.
The report projects the global market size and the growth rate for the forecasted period 2020-2025.
Likewise, factors that inhibit the growth of the market, such as high capital investment, are also analyzed in the report.The global Cephalosporin Drugs market report analyzes the global market growth based on various factors - supply chain analysis, price analysis, Porters Five Force Analysis, PESTEL analysis, etc.
The report provides an in-depth analysis of various insights, such as global market trends, growth drivers, opportunities, and other challenges faced by the industry.For Right Perspective & Competitive Insights, Request a Sample @: https://introspectivemarketresearch.com/request/210Key Player Mentioned: Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz, Orchid Company, Lupin, TEVA, HPGC, Aurobindo, LKPC, Alkem, CSPC, Taj Pharma, DHANUKA LABORATORIES, CordenPharma, SRS Pharmaceuticals, Ankur Drugs and PharmaProduct Segment Analysis: 1st Generation, 2nd Generation, 3rd Generation, 4th GenerationApplication Segment Analysis: Hospital Pharmacy, Retail Pharmacy, Online PharmacyRegional Segment Analysis: USA, Europe, Japan, China, India, South East AsiaThis Cephalosporin Drugs report provides useful insights on supply chain and information of companies working on the same marketplace.
Clear data on financial dynamics, business ups and downs, product demands supply chain, product sales, global market statistics, and market growth accelerators is eloquent.
Descriptions of past, present, and future trends, along with various competitive factors and limitations, show how these factors affect Cephalosporin Drugs market development.The reference for this report is reliable; data are taken from authentic sources and can be helpful for decision making.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
Click here to know more on Non-Small Cell Lung Cancer pipeline NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many othersKey Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.Market DriverMarket Barrier The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.Reimbursement scenario and Key Opinion Leader Views Table of ContentsKey InsightsExecutive Summary of NSCLCSWOT Analysis of NSCLCNSCLC: Market Overview at a Glance4.1.
Total Market size of NSCLC in JapanALK-Mutation—Market Size21.1.
Report MethodologyDelveInsight CapabilitiesDisclaimerAbout DelveInsight Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-marketRelated Reports:Non-Small Cell Lung Cancer Epidemiology Forecast to 2030Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020Non-Small Cell Lung Cancer Pipeline Insights, 2020About DelveInsightDelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment.
